Min Yuen Teo
About
Min Yuen Teo is a scholar working on Surgery, Oncology and Cancer Research.
According to data from OpenAlex, Min Yuen Teo has authored 91 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Surgery, 47 papers in Oncology and 23 papers in Cancer Research. Recurrent topics in Min Yuen Teo's work include Bladder and Urothelial Cancer Treatments (48 papers), Urinary and Genital Oncology Studies (25 papers) and Cancer Immunotherapy and Biomarkers (23 papers). Min Yuen Teo is often cited by papers focused on Bladder and Urothelial Cancer Treatments (48 papers), Urinary and Genital Oncology Studies (25 papers) and Cancer Immunotherapy and Biomarkers (23 papers). Min Yuen Teo collaborates with scholars based in United States, Ireland and United Kingdom. Min Yuen Teo's co-authors include Philip W. Kantoff, Dana E. Rathkopf, Gopa Iyer, Jonathan E. Rosenberg, Dean F. Bajorin, Hikmat Al‐Ahmadie, David B. Solit, Irina Ostrovnaya, Samuel A. Funt and Michael F. Berger and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.
In The Last Decade
Min Yuen Teo
86 papers receiving 1.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Min Yuen Teo United States | 16 | 925 | 672 | 621 | 602 | 394 | 91 | 1.9k | ||
| Teruo Inamoto Japan | 24 | 525 0.6× | 542 0.8× | 505 0.8× | 913 1.5× | 512 1.3× | 124 | 2.1k | ||
| Laurens V. Beerepoot Netherlands | 22 | 778 0.8× | 574 0.9× | 396 0.6× | 822 1.4× | 457 1.2× | 84 | 2.1k | ||
| Andrew C. Birkeland United States | 27 | 533 0.6× | 505 0.8× | 544 0.9× | 626 1.0× | 331 0.8× | 116 | 2.0k | ||
| Florian Heitz Germany | 33 | 1.1k 1.2× | 540 0.8× | 1.0k 1.6× | 482 0.8× | 431 1.1× | 180 | 3.2k | ||
| Shinichi Tsutsui Japan | 23 | 982 1.1× | 565 0.8× | 549 0.9× | 651 1.1× | 408 1.0× | 96 | 2.0k | ||
| Xue Hou China | 26 | 1.3k 1.4× | 1.0k 1.5× | 387 0.6× | 376 0.6× | 317 0.8× | 104 | 2.1k | ||
| David D. Chism United States | 17 | 554 0.6× | 490 0.7× | 681 1.1× | 687 1.1× | 232 0.6× | 30 | 1.7k | ||
| Nicola Battelli Italy | 23 | 1.0k 1.1× | 814 1.2× | 291 0.5× | 512 0.9× | 553 1.4× | 91 | 1.9k | ||
| Thomas J. Ow United States | 23 | 695 0.8× | 384 0.6× | 654 1.1× | 714 1.2× | 395 1.0× | 87 | 2.0k | ||
| Khaldoun Almhanna United States | 27 | 982 1.1× | 1.1k 1.7× | 1.2k 1.9× | 596 1.0× | 332 0.8× | 168 | 2.5k |
Countries citing papers authored by Min Yuen Teo
Since
Specialization
Citations
This map shows the geographic impact of Min Yuen Teo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Min Yuen Teo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Min Yuen Teo more than expected).
Fields of papers citing papers by Min Yuen Teo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Min Yuen Teo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Min Yuen Teo. The network helps show where Min Yuen Teo may publish in the future.
Co-authorship network of co-authors of Min Yuen Teo
This figure shows the co-authorship network connecting the top 25 collaborators of Min Yuen Teo. A scholar is included among the top collaborators of Min Yuen Teo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Min Yuen Teo. Min Yuen Teo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Das, Jeeban Paul, Thomas Powles, Dean F. Bajorin, et al.. (2024). Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 42(16_suppl). 4581–4581.
2.
Guercio, Brendan J., Min Yuen Teo, Ashley Marie Regazzi, et al.. (2024). Associations of dietary fructose with survival of patients (pts) with metastatic cancer of the urothelium (UC) and renal cell carcinoma (RCC) on immune checkpoint blockade (ICB).. Journal of Clinical Oncology. 42(16_suppl). 4571–4571.
3.
O’Reilly, David, Min Yuen Teo, Grainne M. O’Kane, et al.. (2024). Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis. Frontiers in Oncology. 14. 1380453–1380453.
4.
Guercio, Brendan J., Min Yuen Teo, Ashley Marie Regazzi, et al.. (2023). Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB).. Journal of Clinical Oncology. 41(16_suppl). 4598–4598.
5.
Guercio, Brendan J., Eugene J. Pietzak, Samantha Brown, et al.. (2022). Neoadjuvant nivolumab (N) +/- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology. 40(6_suppl). 498–498.
6.
Teo, Min Yuen, Hikmat Al‐Ahmadie, Kenneth Seier, et al.. (2021). Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. British Journal of Cancer. 124(7). 1214–1221.
7.
Teo, Min Yuen, Sean M. McBride, Anuradha Gopalan, et al.. (2021). 637P Biochemical response (PSA0) and testosterone (T) recovery in Metacure, a multi-arm multi-modality (MM) therapy (tx) for very high risk localized (HRL) and low volume metastatic (LVM) prostatic adenocarcinoma. Annals of Oncology. 32. S667–S668.
8.
Almassi, Nima, Eugene J. Pietzak, Nikolaus Schultz, et al.. (2019). PD47-03 CHARACTERIZING THE LANDSCAPE OF ACTIONABLE GENOMIC ALTERATIONS TO IDENTIFY OPPORTUNITIES FOR TARGETED THERAPY TRIALS IN PATIENTS WITH LOCALIZED BLADDER CANCER. The Journal of Urology. 201(Supplement 4).
9.
Teo, Min Yuen & Jonathan E. Rosenberg. (2018). Nivolumab for the treatment of urothelial cancers. Expert Review of Anticancer Therapy. 18(3). 215–221.
10.
Teo, Min Yuen & Jonathan E. Rosenberg. (2018). EMA and FDA prune the checkpoint inhibitor treatment landscape. Nature Reviews Urology. 15(10). 596–597.
11.
Teo, Min Yuen & Jonathan E. Rosenberg. (2018). Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma. Urologic Clinics of North America. 45(2). 287–295.
12.
Teo, Min Yuen, Kenneth Seier, Irina Ostrovnaya, et al.. (2018). Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of Clinical Oncology. 36(17). 1685–1694.
13.
Teo, Min Yuen, Richard Bambury, Emily C. Zabor, et al.. (2017). DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research. 23(14). 3610–3618.
14.
Owczarek, Tomasz B., Takashi Kobayashi, Ricardo J. Ramirez, et al.. (2017). ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. Cancer Research. 77(4). 1035–1046.
15.
Teo, Min Yuen, Xueli Hao, Neil Desai, et al.. (2017). Small cell carcinoma of the bladder (SCCB): Clinical, histopathologic, and genomic predictors of clinical outcomes.. Journal of Clinical Oncology. 35(6_suppl). 294–294.
16.
Teo, Min Yuen, Matthew J. O’Shaughnessy, Sean M. McBride, H. Alberto Vargas, & Howard I. Scher. (2017). Drug development for noncastrate prostate cancer in a changed therapeutic landscape. Nature Reviews Clinical Oncology. 15(3). 168–182.
17.
Teo, Min Yuen, Sinéad Toomey, Shereen Rafee, et al.. (2017). Impact and correlation of mutational load (ML) and specific mutations (mts) assessed by limited targeted profiling (LTP) with PD-L1 tumour expression (exp) in resected non-small cell lung carcinoma (NSCLC).. Journal of Clinical Oncology. 35(15_suppl). 11587–11587.
18.
Teo, Min Yuen & Eileen M. O’Reilly. (2016). Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?. Journal of Gastrointestinal Oncology. 7(5). 738–749.
19.
Teo, Min Yuen, Niall Swan, & Ray McDermott. (2011). Sustained response of adenocarcinoma of the urinary bladder to FOLFOX plus bevacizumab. Nature Reviews Urology. 8(5). 282–285.
20.
Teo, Min Yuen. (2010). A Case of Metastatic Renal Cell Cancer Presenting as Jaundice. World Journal of Oncology. 1(5). 218–220.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Teruo Inamoto Breakdown of academic impact, for papers by Laurens V. Beerepoot Breakdown of academic impact, for papers by Andrew C. Birkeland Breakdown of academic impact, for papers by Florian Heitz Breakdown of academic impact, for papers by Shinichi Tsutsui Breakdown of academic impact, for papers by Xue Hou Breakdown of academic impact, for papers by David D. Chism Breakdown of academic impact, for papers by Nicola Battelli Breakdown of academic impact, for papers by Thomas J. Ow Breakdown of academic impact, for papers by Khaldoun Almhanna